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Abstract
Background: Mutations in the eukaryotic translation initiation factor 2α kinase 4 (EIF2AK4) gene have recently been
identified in recessively inherited veno-occlusive disease. In this study we assessed if EIF2AK4 mutations occur also in a
family with autosomal dominantly inherited pulmonary arterial hypertension (HPAH) and incomplete penetrance of
bone morphogenic protein receptor 2 (BMPR2) mutations.
Methods: Clinical examinations in a family with 10 members included physical examination, electrocardiogram,
(stress)-echocardiography and lung function. Manifest PAH was confirmed by right heart catheterisation in
three affected subjects. Genetic analysis was performed using a new PAH-specific gene panel analysis with
next generation sequencing of all known PAH and further candidate genes. Identified variants were confirmed
by Sanger sequencing.
Results: All living family members with manifest HPAH carried two pathogenic heterozygous mutations: a frame shift
mutation in the BMPR2 gene and a novel splice site mutation in the EIF2AK4 gene. Two family members who carried
the BMPR2 mutation only did not develop manifest HPAH.
Conclusions: This is the first study suggesting that EIF2AK4 can also contribute to autosomal dominantly inherited HPAH.
Up to now it has only been identified in a recessive form of HPAH. Only those family members with a co-occurrence of
two mutations developed manifest HPAH. Thus, the EIF2AK4 and BMRPR2 mutations support the “second hit” hypothesis
explaining the variable penetrance of HPAH in this family. Hence, the assessment of all known PAH genes in families with
a known mutation might assist in predictions about the clinical manifestation in so far non-affected mutation carriers.
Keywords: Hereditary pulmonary arterial hypertension, Next generation sequencing, Pulmonary veno-occlusive disease,
Two-gene model
Background
Pulmonary arterial hypertension (PAH) is a rare disease
characterised by an elevated pulmonary artery mean pres-
sure caused by the obstruction of small pulmonary arteries
leading to right heart failure. The disease may occur spor-
adically (idiopathic), associated with other diseases or in a
heritable form. Hereditary pulmonary arterial hypertension
(HPAH) is considered an autosomal dominantly inherited
disease with incomplete penetrance. Mutations in the bone
morphogenic protein receptor type 2 (BMPR2) gene have
been established as the most common cause of PAH since
the discovery of the first mutations in the year 2000 [1–5].
Up to 87 % of HPAH families and 25 % of idiopathic PAH
patients show a genetic defect in BMPR2 [6, 7]. Further
mutations of genes within the BMPR2 pathway may lead to
PAH manifestation [8] for example in the co-receptors
ACVRL1 and ENG. Through the advent of new sequencing
technologies, such as the next generation sequencing
(NGS) the sequencing of entire exomes became feasible.
This led to the discovery of new PAH causing genes outside
the canonical BMPR2 pathway such as the potassium chan-
nel KCNK3 [9] or cell membrane protein CAV1 gene [10].
In the same manner, mutations in the eukaryotic transla-
tion initiation factor 2α kinase 4 (EIF2AK4) gene have
recently been identified as disease causing in families
with recessively inherited veno-occlusive disease [11]
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and pulmonary capillary haemangiomatosis [12]. Both
diseases are classified as a subgroup of pulmonary
hypertension next to PAH in the current guidelines
[13]. Up to date only one specific mutation within
EIF2AK4 has been identified in 6 families with auto-
somal recessive PAH from the same itinerant Iberian
community [14, 15]. The penetrance of BMPR2 muta-
tions is age dependent and has been estimated to
range between 27 % in women and 14 % in men at
the time of first PAH diagnosis [16] but may be as
high as 43–50 % in some families [17, 18]. Thus, not
all mutation carriers will develop the disease during
their life time. The causes for this phenomenon still
remain unclear. Possible modifiers which lead to dis-
ease manifestation could be additional mutations in
the same pathway [19–21], so called “second hits” or
other external stimuli.
In this study, we therefore investigated the penetrance in
a HPAH family with a known BMPR2mutation by a careful
clinical and genetic assessment. Our aim was to elucidate
whether we can detect further autosomal dominantly inher-
ited gene defects in this family which may explain the
clinical disease manifestation and incomplete penetrance.
Methods
Subjects and clinical characterisation
Members of a family with autosomal dominantly inher-
ited HPAH were clinically and genetically assessed. All
living genetically related family members were invited to
participate. After written informed consent was obtained
family members underwent clinical assessment and gen-
etic counselling. A three generation pedigree was drawn
including nine family members of the index patient.
EDTA-blood was taken for genetic analysis.
Clinical procedures consisted of recording the family
and medical history, physical examination, laboratory
parameters including N-type pro brain natriuretic peptide
(NT-proBNP), 12-lead electrocardiogram, lung function
test, arterial blood gases, 6-min walking distance,
echocardiography, stress-Dopplerechocardiography and
cardiopulmonary exercise testing as described previously
[22]. High resolution computer tomography of the lung
was conducted to exclude pulmonary veno-occlusive
disease. Left heart catheterisation was performed in all
patients with suspected left heart diseases and when
clinically indicated. Manifest HPAH was diagnosed
according to the current guidelines [13]. Right heart
catheterisation was performed in the living HPAH patients
to confirm diagnosis and for follow-up.
Genetic assessment
Genomic DNA was isolated from peripheral blood using
a salting out procedure [23] (Autopure, LGC, Germany).
Sanger sequencing for BMPR2 (ENST00000374580) was
conducted in the index patient using Big Dye Termin-
ator V1.1 cycle sequencing kit and ABI 3130xl genetic
analyzer (ThermoFisher Scientific, USA). Duplications
and deletions were screened by multiplex ligation-
dependent probe amplification (MLPA, kit P093-C2,
MRC-Holland, the Netherlands).
A new PAH gene panel diagnostic based on next gener-
ation sequencing was designed to analyse second hit muta-
tions in 11 PAH (ACVRL1 or ALK1, BMPR1B, BMPR2,
CAV1, EIF2AK4, ENG, KCNA5, KCNK3, SMAD1, SMAD4,
SMAD9) and 20 further candidate genes in the index pa-
tient. DNA was enriched with a customised SureDesign
panel (Agilent Technologies, USA) and sequenced on the
MiSeq (Illumina, USA). Exonic regions and exon-intron
boundaries were analysed with SeqPilot 4.1.2 (JSI medical
systems GmbH, Germany). Variants were characterised fol-
lowing the recommendations of the Human Genome Vari-
ation Society (HGVS version 2.15.11) [24]. Non-
synonymous missense variants with a population frequency
<5 % were assessed regarding their evolutionary conserva-
tion, location within functional gene domains and func-
tional consequence using four in silico prediction
programs: MutationTaster, SIFT, Align GVGD and Poly-
Phen2 implemented in Alamut Visual 2.7.1 (interactive
biosoftware, France). Variants were confirmed by Sanger
sequencing in the index patient and assessed in family
members to clarify mutation status. Any variants disrupt-
ing gene function were considered mutations.
Functional assessment of mutations
RNA was isolated from EDTA blood using standard
procedures. Copy DNA (cDNA) was generated with a
reverse transcriptase reaction adding hexamers for
10 min at 65 °C, a cDNA-Mix (Invitrogen, USA) for 2 h
at 37 °C and a final reaction for 10 min at 65 °C.
A PCR was designed to assess the cDNA corresponding
to the messenger RNA of EIF2AK4 (ENST00000263791,
NM_001013703). The PCR product span the exon 38 using
a forward primer annealing in exon 36 (5′ GACCTCC
CTTGCCAACTTAC 3′) and a reverse primer annealing in
exon 39 (5′ AGAT TCTGTAGTAGTCATCTCTATAGC
3′). The expected size of the intact PCR product was
266 bp and the one of the PCR product skipping exon 38
was 147 bp. Primer annealing and effect of the splice site
mutation are displayed in Fig. 1. cDNA was denatured for
5 min at 95 °C, and subsequently amplified in 35 cycles
(1 min at 95 °C, 1 min at 56.5 °C, 1.5 min at 72 °C; final
elongation 10 min at 72 °C). While several transcripts exist
for EIF2AK4 the considered isoform is the most common
one in humans since it is referred to as reference sequence
by NCBI RefSeq. NCBI RefSeq is a database which we used
as reference standard for reporting the location of medically
important variations. PCR products were sequenced with
Eichstaedt et al. Respiratory Research  (2016) 17:141 Page 2 of 8
Sanger sequencing to identify the altered base pair se-
quence of the messenger RNA.
Statistical analyses
Significance of co-occurance of BMPR2 and EIF2AK4 was
calculated by using an estimated heterozygote frequency of
EIFAK4 mutations retrieved from the Exome Aggregation
Consortium (ExAC) database [25] and taking into account
the number of genes on the panel by correcting for multi-




Clinical and genetic data are presented in Fig. 2, clinical pa-
rameters in Table 1. PAH was excluded in healthy family
members by regular clinical assessments including phys-
ical examination, lung function tests, electrocardiogram,
and in particular by echocardiography, stress-Doppler-
echocardiography, spiroergometry and NT-proBNP
values. Diagnosis of PAH was confirmed by right heart
catheterisation in patients II:4, III:2 and III:3. The disease
was very severe in all three patients but could be stabilised
with medication in patients II:4, and III:2. Patient III:3
showed a rapid progression and received a lung trans-
plantation 1.5 years after diagnosis. She died only one year
after transplantation due to a rejection of the donor organ
(Fig. 2). Patient II:4 and III:2 were under dual therapy at
the time of this writing. Stable haemodynamic parameters
were observed in the latest catheter of patient II:4 with a
mean pulmonary artery pressure (mPAP) of 46 mmHg,
pulmonary arterial wedge pressure (PAWP) of 12 mmHg,
cardiac output 4.6 l/min, cardiac index 2.3 l/min/m2 and
pulmonary vascular resistance of 591 dynes. Patient III:2
has improved under therapy to a mPAP of 55 mmHg,
PAWP of 14 mmHg, cardiac output 6.0 l/min, cardiac
index 2.9 l/min/m2 and pulmonary vascular resistance
of 547 dynes.
Pulmonary veno-occlusive disease (PVOD) was ex-
cluded in the patients on three grounds. Firstly, high reso-
lution computer tomography showed no morphological
changes typical for PVOD. Secondly, diffusion capacity of
the lung for carbon monoxide (DLCO) values were greater
than 50 % predicted. Values around 50 % are often seen in
PVOD [26]. Thirdly, patients II:4 and III:2 have received
PAH medication for 8 years and were stable under dual
therapy. Whereas in PVOD a worsening of symptoms is
often observed, once PAH medication has been given.
Genetic findings
All living family members with manifest HPAH (II:4, III:2
in Fig. 2) carried a heterozygous mutations in BMPR2 and
EIF2AK4. In contrast, two non-diseased family members
(III:1 and III:4) carried only the BMPR2 mutation and no
mutation in EIF2AK4. None of these family members devel-
oped manifest HPAH (Fig. 2) at of the time of this writing.
The first familial mutation lay within exon 12 of the
BMPR2 gene (c.2308delC, p.(Arg770Glyfs*2)) and led to the
deletion of a cytosine resulting presumably in a premature
stop codon two amino acids downstream. The second muta-
tion was located one base pair behind the end of exon 38 of
the gene EIF2AK4 (c.4892+1G>T) resulting in the loss of the
complete exon 38 (Fig. 3). Due to this exon loss sequencing
results suggested a frame shift and subsequent introduction
of a premature stop codon in exon 39 at amino acid position
1599 instead of position 1650 in the regular protein; hence, a
disrupted protein after the end of exon 37 is predicted.
While DNA was only available from five family mem-
bers the pedigree analysis revealed two further obligate
carriers of the BMPR2 mutation. The grandfather (I:1)
and the aunt (II:2) of the index patient must have been
carriers for the cousin (III:1) to harbour the mutation.
At the same time, the EIF2AK4 mutation was most likely
also present in the grandfather (I:1), who had died aged
49 years due to liver cirrhosis. Since the mother of the
index patient (II:4) only developed manifest PAH at the
Fig. 1 Functional assessment of splice site mutation. The top level displays the location of the exons 36-39 of the EIF2AK4 gene within the genome
including intronic sequences. The mutation (c.4892+1G>T) is indicated by the red arrow. The second level displays copy DNA (cDNA) generated by a
reverse transcriptase from extracted messenger RNA. A) shows the intact sequence and PCR product if no mutation is present, including exon 38. B)
displays the effect of the mutation leading to a loss of exon 38. Exon sizes are proporational to their respective number of amino acids
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Fig. 2 Pedigree of HPAH family. Affected individuals have filled symbols, healthy individuals empty symbols. Age, mutation status and age of PAH
onset are provided below. Patient III:3 received a lung transplantation one year after diagnosis and died of transplant rejection one year later. The
BMPR2 mutation leads to a premature stop codon and the EIF2AK4 mutation to a splice site change and subsequent loss of exon 38 presumably
followed by a frame shift and premature insertion of a stop codon
Table 1 Clinical parameters
Parameter II:4 III:2 III:4
Age at diagnosis 49 29 –
mPAP [mmHg] a 55 63 –
PAWP [mmHg] b 13 14 –
CO [l/min] 6.1 5.1 –
CI [l/min/m2] 3.2 2.4 –
PVR [dynes] 551 736 –
SaO2 [%] 97 98 96
sPAP [mmHg] at rest c 94 47 20
sPAP [mmHg] during exercise c 100 95 29
Peak VO2 [ml/min/kg] 18 17 24
RV area [cm2] 18 27 15
TAPSE [cm] 3.0 2.4 2.3
DLCO predicted [%] 77 60 91
NT-proBNP [ng/l] 89 58 31
6-MWD [m] 480 560 –
Medication Silenafil, Macitentan Sildenafil, Macitentan –
amPAP ≥25 mmHg characterises pulmonary hypertension
bPAWP >15 mmHg together with mPAP ≥25 mmHg characterises post-capillary PH due to left heart disease; PAWP ≤15 mmHg together with mPAP ≥25 mmHg
characterizes pre-capillary PH
csPAP >40 mmHg at rest and sPAP >45 mmHg at low workloads is considered here as abnormal and exercise induced pulmonary hypertension, respectively [27].
However, cut-offs are not clearly defined in current guidelines
mPAP, (sPAP) mean (systolic) pulmonary arterial pressure, PAWP pulmonary arterial wedge pressure, CO cardiac output, CI cardiac index, SaO2 oxygen saturation,
VO2 oxygen uptake, PVR pulmonary vascular resistance, RV right ventricular, TAPSE tricuspid annular plane systolic excursion, DLCO diffusion capacity of the lung
for carbon monoxide, NT-proBNP N-type pro brain natriuretic peptide, 6-MWD 6 min walking distance
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age of 49 years, it is likely that the grandfather would
have developed PAH due to the inferred presence of
both mutations at a later stage in his life or had already
developed the disease but had not been diagnosed until
his death. Alternatively, the EIF2AK4 mutation might
have arisen de novo in II:4 or as a germ line mosaicism
in either grandparent of the index patient.
In HPAH we expect a BMPR2 mutation with a probabil-
ity of 85 % [7, 8]. Under the null hypothesis stating that
the mutation in EIF2AK4 does not contribute to disease
manifestation but instead represents a random event for
the proband, the chance to observe the association of the
two mutations has the probability of 0.00046. Taking the
number of genes on the panel into account this associ-
ation of both mutations under the null hypothesis reveals
p = 0.00046*30 = 0.014, which is significant below the 5 %
level. Hence, the co-occurrence of both mutations in
affected family members is a significant association.
Moreover, EIF2AK4 co-segregates with disease conditioned
on all BMPR2 positive family members supporting the
hypothesis of a second hit model, in which the diplotype of
mutations in both genes has a high penetrance for PAH.
Discussion
This is the first report of an autosomal dominantly inher-
ited EIF2AK4 mutation as second hit in a family with
HPAH and known BMPR2 mutation. Only those family
members with a co-occurrence of a mutation in BMPR2
and EIF2AK4 were clinically affected and developed mani-
fest HPAH, whereas carriers of the BMPR2 mutation only
had no symptoms of PAH. Thus, the results of this study
offer an explanation for the reduced penetrance of the dis-
ease in this family and show that EIF2AK4 may play a role
also in families with autosomal dominantly inherited PAH.
EIF2AK4 mutation in autosomal dominant HPAH
EIF2AK4 was first described in the autosomal recessively
inherited pulmonary veno-occlusive disease (PVOD) [11]
and pulmonary capillary haemangiomatosis [12]. Recently a
single recessively inherited EIF2AK4 mutation (c.3344C>T,
p.(P115L)) was repeatedly identified in six consanguineous
HPAH families with autosomal recessive mode of inherit-
ance [14, 15]. Only homozygous mutation carriers devel-
oped the disease plus a single heterozygous carrier of a
distinct EIF2AK4 mutation, in whom the authors suspected
a second non-identified mutation in the same gene [14].
Therefore, up to now EIF2AK4 mutations have been
believed to be a very rare in HPAH. Apart from the men-
tioned family we were able to identify a nonsense mutation
in exon 8 in the EIF2AK4 gene in another PAH patient with
sporadic IPAH who had no other mutation in known
candidate genes (data not shown). Thus, this gene might be
more often affected than initially thought and contributes
to the disease in an autosomal dominant manner. In
contrast, BMPR2 mutations occur in up to 85 % of familial
cases and are autosomal dominantly inherited [7, 8]. How-
ever, many BMPR2 gene carriers have no clinical symptoms
and do not develop manifest PH even during a more than
10 year follow-up period [22]. Hence, the family described
here provides an explanation for the decreased penetrance
and suggests an autosomal dominantly contribution of
EIF2AK4 to disease manifestation.
EIF2AK4 mutation as “second hit” may explain variable
penetrance
Up to date only four families with second hits have been
described [19, 20]. This might be due to the fact that usually
only 3 genes (BMPR2, ACVRL1, ENG) are analysed rou-
tinely in PAH patients in a sequential processes, i.e. if one
mutation is discovered the other genes are not assessed.
Thus, second hit mutations might be overlooked in general
in the current routine diagnostic setting and particularly in
genes such as EIF2AK4, which are usually not included in
the diagnostic analysis.
While second hits are still rarely described in PAH this
model is often found in other diseases such as the nephrotic
syndrome [28] or the long QT-syndrome [29]. At the same
Fig. 3 Effect of the EIF2AK4 mutation c.4892+1G>T on cDNA level.
Next to the ladder the affected individual II:4 shows a heterozygous
PCR product for the cDNA of EIF2AK4 exons 36–39. The upper band
shows the wildtype sequence (266 bp) while the lower band shows
a product without exon 38 (147 bp). The healthy family member III:4 is
homozygous for the wild type PCR product indicating no loss of exon 38
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time the decreased penetrance in PAH is an acknowledged
pattern. Thus, second hits or modifier genes might be more
common in PAH than known to date. We therefore con-
trast two genetic models: Firstly, we propose the “second
hit model” to explain the low disease penetrance in PAH. In
this model a single mutation in each gene on its own has a
very low penetrance. Two mutations however, lead to a syn-
ergistic effect resulting in a high disease penetrance. The
second model is the “single gene model”, representing the
classical view for PAH suggesting BMPR2 mutations alone
are responsible for disease manifestation. Under this as-
sumption, the EIF2AK4 mutation would randomly occur in
this family and not impact PAH manifestation. In the latter
model the penetrance for the BMPR2 variant must be mod-
erate, since 4 (obligate) carriers of the mutation did not de-
velop PAH up to ages 31, 37, 49 and 59.
Considering both models, it is significantly unlikely
that both mutations in two known PAH genes occurred
by chance in this family. Moreover, the EIF2AK4 muta-
tion clearly co-segregates with the disease in BMPR2
positive family members suggesting a second hit model.
We have not observed an EIF2AK4 mutation alone
within this family, albeit in a different IPAH patient (data
not shown) indicating at least a low penetrance to be
present. Disease severity might moreover be influenced by
the location of the respective mutations within the protein
and thus their variable impact on protein function [8].
Therefore, we hypothesise according to the second hit
model the penetrance to be intermediate if only BMPR2
was positive, very low if only EIF2AK4 was positive, and
very high if EIF2AK4 and BMPR2 each harboured a muta-
tion. However, a greater cohort study would be required
assessing IPAH/HPAH patients for all known PAH genes
to investigate the frequency of EIF2AK4 mutations, second
hits in PAH and their contribution to disease manifestation
within affected families. Furthermore, animal studies would
be required to investigate the proposed synergistic effect of
two mutations in the same individual.
Not only the number of mutations in different genes but
already the state (homo-/heterozygous) of the allele can
affect disease severity [30] and even define which disease is
developed. For example BRCA2 may cause Fanconi aene-
mia in the homozygous state and familial breast and ovar-
ian cancer in the heterozygous state [31]. In other diseases
variants within the same gene might act dominantly or re-
cessively depending on their localisation within the gene,
e.g. MAB21L2 can lead to eye malformations as a dominant
or recessive trait [32]. Moreover, the 1000 genome project
revealed around half a million variants in regulatory sites
which most likely act as modifiers on gene expression and
are not routinely considered in the diagnostic setting [33].
Thus, most Mendelian diseases are more complex than ini-
tially thought. The same most likely applies to PAH which
is characterised by a reduced penetrance. Non-diseased
mutation carriers may therefore only be provided with
probabilities regarding disease manifestation by genetic
counsellors. Any elucidation of further mechanisms refin-
ing the predictions of disease manifestation would reduce
the uncertainty for patients and genetic counsellors. While
we propose a synergistic effect of the two mutations, cur-
rently no different therapeutic approach is indicated. A
close monitoring of these patients will be required to allow
therapy escalation if necessary. A recent publication sup-
ports increased disease severity in patients with several mu-
tations, younger age of onset and less effective treatment
response in comparison to patients with a single mutation
[34]. Thus, a comprehensive overview will be required with
a large cohort of patients analysing current treatment op-
tions and genetic mutation status to re-evaluated current
therapeutic strategies.
Loss of protein function by EIF2AK4 mutation
The gene EIF2AK4 encodes a kinase termed general control
nonderepressable 2 (GCN2) which phosphorylates the
eukaryotic translation initiation factor 2α leading to a global
down regulation of protein synthesis in response to amino
acid starvation, hypoxia and viral infection but the up-
regulation of specific stress response proteins [35]. Gene
expression is increased in smooth muscle cells in the vessel
wall and interstitial tissue [11]. While the gene function has
been studied a clear link to PVOD or PAH still remains to
be detected. However, an interaction between EIF2AK4 and
the BMPR2 pathway genes SMAD1, SMAD4, ACVRL1 and
ENG has been observed [11, 36]. Thus, an impaired func-
tioning of both, BMPR2 and GCN2 (EIF2AK4), might po-
tentiate its effect on the transcription of target genes of the
BMPR2 pathway.
The EIF2AK4 mutation of this family leads to the loss of
a splice site and subsequently the loss of exon 38, presum-
ably a frame shift and premature stop codon. In the last
exons of the functional gene (31–39) lies the ribosomal
binding domain and the dimerisation domain between
amino acids 1396–1643 [37]. The last 51 amino acids of
this domain were missing or partly exchanged by wrong
amino acids in the affected members of this HPAH family.
The domain is essential to recruit ribosomes for protein
synthesis [38], thus a partial deletion will at least moder-
ately affect protein-ribosome binding if not fully impair it.
Moreover, in the same region the dimerisation domain is
located. This facilitates the formation of a homodimer (2
EIF2AK4 proteins bind to each other) and thus a functional
protein [38]. The formation of homodimers has been
shown to be conserved in mice and yeast [39]. Single amino
acid substitutions in the C-terminal domain in yeast already
led to an inability of the protein to dimerise and to be func-
tionally active [38]. The gene sequence of the C-terminal
domain is highly conserved from mice to mammals sug-
gesting corresponding functional impairments in humans
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[40]. A total deletion of this region in our HPAH family
thus likely leads to a loss of function in the mutated gene.
Conclusions
We were able to show EIF2AK4 contributes to disease
manifestation in this HPAH family in an autosomal domin-
ant manner. We report a new mutation within EIF2AK4
leading to HPAH as a second hit together with a mutation
in BMPR2 providing an explanation for the observed pene-
trance in this family. Only those family members with a co-
occurrence of two mutations developed manifest HPAH.
The occurrence of several mutations in PAH associated
genes might be more frequent than initially thought. Thus,
a simultaneous assessment of all PAH associated genes in
more patients might shed light on the long standing ques-
tion surrounding the reduced penetrance.
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